Our Trials

rs154038_pg1_9383-hpr
This is a randomised, multi-centre, phase III trial (two arm study) for patients with MRI defined locally advance rectal cancer. The study aims to determine whether the addition of a second drug (irinotecan) to the standard treatment of oral chemotherapy using capecitabine and radiotherapy improves outcome resulting in fewer cancer recurrences (regrowth) after the operation and if patients live longer.

 

Randomisation will be 1:1 and will be performed centrally at the UCL CTC and this must be performed prior to commencement of any trial treatment. Randomisation will be based on pre-defined stratification factors and patients will be allocated on one of 2 arms:

  • ARM A: Capecitabine CRT

–          Capecitabine 900mg/m2 orally bd 5 days/week (Mon-Fri) for 5 weeks

–          Pelvic radiotherapy 45Gy in 25 fractions

 

  • ARM B: Irinotecan Capecitabine CRT

–          Irinotecan 60mg/m2 weekly iv(weeks 1,2,3,4)

–          Capecitabine 650mg/m2 orally bd 5 days/week (Mon-Fri) for 5 weeks

–          Pelvic radiotherapy 45Gy in 25 fractions

 

Participant sites will be requested to complete a self-assessment monitoring report periodically, at a frequency detailed in the monitoring plan (which has not been submitted yet). Sites will also be requested to submit specific trial documentation to check for consistency and completeness. Any inconsistencies or non-compliance suspicions could result in on-site monitoring visits.

FOCUS4 is a molecularly stratified, multi-arm, multi-stage design, multi-site randomised trials programme for patients with colorectal cancer (CRC). During the initial registration period (master protocol), all patients are treated with 16 weeks of standard 1st line chemotherapy. During this time they will be registered and consented to send their tumour block sample for biomarker panel assessment.

 

The results of this assessment will be used to classify the patient into one of the possible molecular cohorts and they will be offered entry into one of the specific trials. There are four molecular cohorts (A, B, C and D) and a fifth trial (N) which will run concurrently for patients whose biomarker results are unclassifiable or for any patients who are unable or unwilling to travel (their site may not be able to offer the trial specifically appropriate for their molecular cohort).

 

Sites have been classified into three levels. For safety reasons, agents for some of the cohorts(A, B or C)will only be available at level three sites. RSCH has been classed as a level 3 site. This phase 1 work will be carried out in the Clinical Research Centre, University of Surrey.

 

NB: Initially, only trials D and N will open as the Investigational Medicinal Products for the other cohorts have not yet been agreed upon. These are the trials which will include the phase 1 work.

 

The study has a website: www.focus4trial.org

Metastatic colorectal cancer (mCRC) continues to be a serious, life-threatening condition. It is the second most common type of cancer in Europe in both men and women. Standard therapy in patients with unresectable (unable to be removed with surgery) mCRC includes combination regimens with cytotoxic (drugs which include chemicals which are toxic to cells) and targeted agents. In the last decade, substantial advances in the treatment of mCRC have resulted in an improvement in overall survival from 10 to 12 months to more than 20 months. This improvement has
occurred due to the addition of the following chemotherapy drugs; irinotecan, oxaliplatin, bevacizumab, cetumimab and panitumumab to the standard treatment with 5-fluorouracil/folinic acid.

BRAF is a human gene that makes a protein which is involved in sending signals inside cells which are involved in directing cell growth. BRAF mutation lead to cancer cells survival and can be considered an indication for poor prognosis in patients with mCRC.

This is a randomised (like the tossing of a coin), open-label (clinical and participant will know which treatment they have been assigned to), parallel group, 3 arm study in patients with previously treated BRAF mCRC comparing the efficacy and safety of the following chemotherapy arms;
Arm 1 – binimetinib + encorafenib + cetuximab
Arm 2 – encorafenib + cetuximab
Arm 3 – Control Arm (irinotecan/cetumimab or FOLFIRI/CETUMIMAB)

This research is about measuring the impact of cancer and its treatment on patients and their informal caregivers (e.g. spouse, partner, family member, close friend). Having cancer can affect many aspects of life such as finances, work status and patients’ own caring roles with family or friends, which are important to understand but are not well captured by existing measures.
In studies 1-3 of PROACT we developed and evaluated two questionnaires measuring impact on caregiving and other responsibilities and lifestyle disruption for patients and caregivers. We developed the questionnaires through qualitative interview studies and through collaboration with advisors with lived experience of cancer or caring for someone with cancer. We then conducted some research to determine the reliability and validity of the new measures.
These comparisons are important to ensure that when health care professionals and researchers use our questionnaires, they can be confident that they are measuring wellbeing and impact with a reliable measure. Both
questionnaires performed well in this initial evaluation. In this fourth study we wish to repeat the evaluation with a new group of patients and caregivers. We will expand our inclusion criteria to include different types and stages of cancer. We will use the same methodology as study 3 and invite participants to complete the new PROACT measures three times over two months, along with other quality of life questionnaires at two of these time points. This enables us to see how our new measures perform over time; whether they are reliable if completed twice close together and whether they are able to detect change in wellbeing if completed two months apart in participants whose situations are changing. This next stage in validation is essential to ensure that the questionnaires are suitable for use in future research and practice across different types of cancer.

©2018 Royal Surrey County Hospital

Log in with your credentials

Forgot your details?